{
    "symbol": "ACXP",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-11 15:58:09",
    "content": " Additionally, based on the strength of our previously reported Phase 2a results, which demonstrated 100% clinical cure in patients after a 10-day treatment for CDI with no recurrence of infection at the day 38 eight follow visit, we've added a novel exploratory endpoint in the Phase 2b trial of extended clinical cure or ECC for study visits at day 56 and day 84 after the end of treatment for a selected group of subjects to evaluate the longer-term effect of ibezapolstat on the microbiome and on disease recurrence."
}